Company Description
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma.
The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses.
Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
| Country | United States |
| Founded | 2001 |
| IPO Date | Jan 26, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Thomas Zindrick |
Contact Details
Address: 2625 Townsgate Road, Suite 230 Westlake Village, California 91361 United States | |
| Phone | 805 267 9889 |
| Website | genelux.com |
Stock Details
| Ticker Symbol | GNLX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001231457 |
| CUSIP Number | 36870H103 |
| ISIN Number | US36870H1032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas Zindrick J.D. | Chairman, Chief Executive Officer and President |
| Dr. Joseph Cappello Ph.D. | Chief Technical Officer |
| Matthew Pulisic M.B.A. | Chief Financial Officer and Principal Financial and Accounting Officer |
| Sean Ryder J.D. | General Counsel and Corporate Secretary |
| Dr. Yong Yu Ph.D. | Senior Vice President of Clinical Development |
| Prof. Paul Scigalla M.D., Ph.D. | Chief Medical Officer |
| Ralph Smalling B.Sc. | Vice President and Head of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 11, 2025 | ARS | Filing |
| Jul 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 11, 2025 | DEF 14A | Other definitive proxy statements |
| May 6, 2025 | 10-Q | Quarterly Report |
| Apr 29, 2025 | 10-K/A | [Amend] Annual report |
| Mar 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 424B5 | Filing |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 25, 2025 | FWP | Free Writing Prospectus |